Friday, 22 Mar 2019

You are here

The Week in Review - 13 February 2016

The Week in Review - 13 Feb 2016 covers:

1.    Acute sacrolilitis diagnosis by CT or bone scan; causes pyogenic, Brucella, crystals, neoplasia
2.    FDA Advisory Vote on Biosimilar
3.    Bisphosphonates are not associated with gastric or esophageal cancer
4.    Psoriatic arthritis risk of SIE and only 6% added risk when using a TNF inhibitor
5.    RWCS – Trajectory of improvement predicts remission success
6.    Dr. Joel Kremer's blog on the History of Methotrexate
7.    FDA Arthritis Advisory Hearing voted 21-3 in favor of approving CT-P13 as a biosimilar of its reference product Remicade – may lead to approval for RA, Psoriasis, Psoriatic arthritis, adult and pediatric Crohn
8.    2016 RWCS Proceedings – Highlights from Drs. Cush, Kavanaugh, Gladman, Bergman, Troum

  • SURPRISE Study: add on vs single therapy with Tocilizumab
  • Polyarticular JIA – not a good idea to withdraw therapy
  • Very Early RA responds best in the AVERT study – Abatacept + MTX.
  • Psoriasis review by Dr. Gladman
  • Debate on Medical Marijuana
  • OA IA steroid injections are not effective 
  • Stricter warnings for NSAIDs and CV risk
  • Lesinurad is FDA approved as cotherapy for gout
  • Gout co-associations 
The author has no conflicts of interest to disclose related to this subject
Dr. Cush is the Director of Clinical Rheumatology at the Baylor Research Institute and a Professor of Medicine and Rheumatology at Baylor University Medical Center in Dallas, TX. He a Professor of Clinical Medicine at the University of Texas Southwestern Medical School.
Dr. Cush is the Executive Editor of and also Co-Edits the online textbook 
Dr. Cush's research and interests include novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, pregnancy and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
He can be followed on twitter: @RheumNow.

Add new comment